Evidence map›Paper›PMID 35906245›Full record

ArticleNature communications2022

TRIM28-dependent SUMOylation protects the adult ovary from activation of the testicular pathway.

Moïra Rossitto, Stephanie Déjardin, Chris M Rands, Stephanie Le Gras, Roberta Migale, Mahmoud-Reza Rafiee, Yasmine Neirijnck, Alain Pruvost, Anvi Laetitia Nguyen, Guillaume Bossis and 7 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 38 citations in OpenAlex.

  1. Spatiotemporally primed coelomic epithelium and supporting-like cells establish the dual origin of granulosa cells.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. TRIM28 drives immune evasion via PARP1 SUMOylation and NADJournal for immunotherapy of cancer · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 4 countries.

Moïra RossittoInstitute of Human Genetics, CNRS UMR9002 University of Montpellier, 34396, Montpellier, France.
Stephanie DéjardinInstitute of Human Genetics, CNRS UMR9002 University of Montpellier, 34396, Montpellier, France.ORCID 0000-0001-5328-1414
Chris M Rands *Department of Genetic Medicine and Development, Faculty of Medicine, University of Geneva CMU, lab E09.2750.B 1, rue Michel-Servet CH 1211 Geneva 4, Geneva, Switzerland.
Stephanie Le Gras *GenomEast platform, IGBMC, 1, rue Laurent Fries, 67404 ILLKIRCH Cedex, Illkirch-Graffenstaden, France.
Roberta MigaleThe Francis Crick Institute, 1 Midland Road, London, NW1 2 1AT, UK.
Mahmoud-Reza RafieeThe Francis Crick Institute, 1 Midland Road, London, NW1 2 1AT, UK.ORCID 0000-0002-1317-1162
Yasmine NeirijnckDepartment of Genetic Medicine and Development, Faculty of Medicine, University of Geneva CMU, lab E09.2750.B 1, rue Michel-Servet CH 1211 Geneva 4, Geneva, Switzerland.ORCID 0000-0001-7236-8451
Alain PruvostUniversité Paris Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, 91191, Gif-sur-Yvette, France.ORCID 0000-0002-7781-7735
Anvi Laetitia NguyenUniversité Paris Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, 91191, Gif-sur-Yvette, France.
Guillaume BossisInstitut de Génétique Moléculaire de Montpellier (IGMM), University of Montpellier, CNRS, Montpellier, France.ORCID 0000-0002-3349-8250
Florence CammasInstitut de Recherche en Cancérologie de Montpellier, IRCM, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier, F-34298, France.ORCID 0000-0003-4117-8182
Lionel Le GallicInstitute of Human Genetics, CNRS UMR9002 University of Montpellier, 34396, Montpellier, France.
Dagmar WilhelmDepartment of Anatomy and Physiology, University of Melbourne, Parkville, VIC, 3010, Australia.ORCID 0000-0002-7757-4075
Robin Lovell-BadgeThe Francis Crick Institute, 1 Midland Road, London, NW1 2 1AT, UK.ORCID 0000-0001-9364-4179
Brigitte Boizet-BonhoureInstitute of Human Genetics, CNRS UMR9002 University of Montpellier, 34396, Montpellier, France.
Serge NefDepartment of Genetic Medicine and Development, Faculty of Medicine, University of Geneva CMU, lab E09.2750.B 1, rue Michel-Servet CH 1211 Geneva 4, Geneva, Switzerland.ORCID 0000-0001-5462-0676
Francis PoulatInstitute of Human Genetics, CNRS UMR9002 University of Montpellier, 34396, Montpellier, France. francis.poulat@igh.cnrs.fr.ORCID 0000-0003-2070-1296
Centre National de la Recherche Scientifique · FRThe Francis Crick Institute · GBUniversity of Geneva · CHCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRInserm · FRInstitut de génétique et de biologie moléculaire et cellulaire · FRThe University of Melbourne · AU

Funding

Cancer Research UK FC001107Medical Research Council FC001107Medical Research Council U117512772Wellcome Trust FC001107
6 · The paper itself

Abstract

Gonadal sexual fate in mammals is determined during embryonic development and must be actively maintained in adulthood. In the mouse ovary, oestrogen receptors and FOXL2 protect ovarian granulosa cells from transdifferentiation into Sertoli cells, their testicular counterpart. However, the mechanism underlying their protective effect is unknown. Here, we show that TRIM28 is required to prevent female-to-male sex reversal of the mouse ovary after birth. We found that upon loss of Trim28, ovarian granulosa cells transdifferentiate to Sertoli cells through an intermediate cell type, different from gonadal embryonic progenitors. TRIM28 is recruited on chromatin in the proximity of FOXL2 to maintain the ovarian pathway and to repress testicular-specific genes. The role of TRIM28 in ovarian maintenance depends on its E3-SUMO ligase activity that regulates the sex-specific SUMOylation profile of ovarian-specific genes. Our study identifies TRIM28 as a key factor in protecting the adult ovary from the testicular pathway.

Indexed as

OvarySumoylationAnimalsFemaleMaleMammalsMiceSertoli CellsTestisTranscription FactorsTripartite Motif-Containing Protein 28Transcription FactorsTrim28 protein, mouseTripartite Motif-Containing Protein 28

Identifiers

PMID35906245
PMCPMC9338040
OpenAlexW4288700137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.